On-Demand Webinar

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

This webinar explained how advanced analytics using real-world data can mitigate challenges in Alzheimer’s disease…

Certara2019 年 5 月 13 日

Blog

Trends for Market Access, HEOR, and Real World Evidence

This blog reviews trends for using health economics and outcomes research and real-world evidence to…

Certara2019 年 5 月 10 日

Blog

Real World Evidence Marches Forward in Drug Development

The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…

Certara2019 年 3 月 20 日

Publication

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Apixaban is an orally available, direct, selective inhibitor of the coagulation factor Xa that reversibly…

Certara2018 年 6 月 2 日

Publication

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

Certara2018 年 2 月 15 日

White Paper

药物资产评估：提高交易的 "成功概率”

Certara’s due diligence/asset evaluation teams are comprised of drug development and commercialization experts who advise…

Certara2017 年 8 月 24 日

White Paper

基于模型的荟萃分析（MBMA）：创新方法的时代来临了

MBMA integrates internal and external drug development data to inform proprietary commercial and R&D decisions.…

Certara2016 年 7 月 14 日

Publication

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

The objective of this study was to assess the relationship between short-term and long-term treatment…

Certara2016 年 7 月 1 日

Publication

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

Gastric emptying (GE) is often reported to be slower and more irregular in premature neonates than…

Certara2015 年 5 月 1 日

Publication

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

PURPOSE: To characterize dose and response for intraocular pressure (IOP) reduction and incidence of hyperemia…

Certara2015 年 5 月 1 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

Certara 服务

使用 RWD 进行高级分析可减轻 AD 药物开发和报销相关的风险

Trends for Market Access, HEOR, and Real World Evidence

Real World Evidence Marches Forward in Drug Development

Apixaban for treatment of venous thromboembolism (VTEtx): Use of MBMA to support Phase 3 dose selection and beyond

Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

药物资产评估：提高交易的 "成功概率”

基于模型的荟萃分析（MBMA）：创新方法的时代来临了

Short-term Efficacy Reliably Predicts Long-term Clinical Benefit in Rheumatoid Arthritis Clinical Trials as Demonstrated by Model-based Meta-analysis

Does Age Affect Gastric Emptying Time? A Model-based Meta-analysis

A Model-based Dose-response Meta-analysis of Ocular Hypotensive Agents as a Drug Development Tool to Evaluate New Therapies in Glaucoma

订阅时事通讯

快捷链接

解决方案

联系我们